Skip to content

Curcumin trial reports lower liver fat in participants with obesity and diabetes

A placebo-controlled trial found changes in liver fat, stiffness and blood sugar, but the abstract does not show how large those changes were.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Curcumin improved liver fat, liver stiffness and a blood-sugar marker compared with placebo in this trial of people with obesity and diabetes. These are measurement-based outcomes, and the abstract does not report fewer liver complications or improved symptoms. Mild digestive discomfort occurred, while the reported safety testing found no clinically significant abnormalities.

Keep in mind

The abstract reports statistical significance without effect sizes or confidence intervals. It does not establish effects on liver complications, and findings from this specific clinical group should not be generalized to everyone.

THE NUMBERS, WITH CONTEXT

What researchers found

p < 0.001

Liver fat content

Curcumin versus placebo in a 12-month trial: liver fat decreased significantly. The abstract does not report the size of the between-group difference.

Int J Mol Sci, 2025 · Original source ↓

Other measurements changed

The trial also measured inflammatory proteins and antioxidant markers, with reported changes favoring curcumin. Those laboratory results accompany the liver findings, but the abstract does not demonstrate which biological changes produced the liver effects.

What safety reporting covers

Safety assessments included liver and kidney function tests. The most frequently reported non-serious adverse event was mild digestive discomfort. The abstract does not give its frequency or establish safety beyond the trial’s observation period.

CHECK THE ORIGINAL

The original publication

Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.

Yaikwawong M, Kamdee K, Chuengsamarn S
Int J Mol Sci · 2025

PubMed ID
41096556
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.